Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Evotec AG : Notification and public disclosure of transactions by persons

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/18/2017 | 02:05pm CEST


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

18.09.2017 / 14:01
The issuer is solely responsible for the content of this announcement.


1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title: Dr.
First name: Werner
Last name(s): Lanthaler

2. Reason for the notification

a) Position / status
Position: Member of the managing body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
Evotec AG

b) LEI
529900F9KI6OYITO9B12 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE0005664809

b) Nature of the transaction
Exercise against Cash Settlement
Transaction linked to the exercise of share option programmes

c) Price(s) and volume(s)
Price(s) Volume(s)
17.7711 EUR 977410.50 EUR

d) Aggregated information
Price Aggregated volume
17.7711 EUR 977410.50 EUR

e) Date of the transaction
2017-09-15; UTC+2

f) Place of the transaction
Outside a trading venue



18.09.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Internet: www.evotec.com

 
End of News DGAP News Service

37749  18.09.2017 


© EQS 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
04/19EVOTEC : and Bayer Advance Third Endometriosis Programme into Phase I Clinical D..
AQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC : and Bayer Advance Third Endometriosis Programme into Phase I Clinical D..
BU
04/18EVOTEC : And bayer advance third endometriosis programme into phase i clinical d..
EQ
04/16EVOTEC : forms collaboration with Petra Pharma on INDiGO platform
AQ
More news
News from SeekingAlpha
04/11Petra Pharma teams up with Evotec to develop lead candidate Petra-01 
03/28Evotec AG 2017 Q4 - Results - Earnings Call Slides 
03/28Evotec's (EVOTF) CEO Werner Lanthaler on Q4 2017 Results - Earnings Call Tran.. 
03/28Evotec AG reports FY results 
03/26Evotec launches accelerated drug development service 
Financials (€)
Sales 2018 324 M
EBIT 2018 57,9 M
Net income 2018 44,0 M
Debt 2018 69,7 M
Yield 2018 -
P/E ratio 2018 46,53
P/E ratio 2019 39,52
EV / Sales 2018 6,79x
EV / Sales 2019 5,87x
Capitalization 2 128 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,5 €
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG5.52%2 615
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.75%14 493
NEKTAR THERAPEUTICS44.36%13 873